Lyell Immunopharma, Inc.LYEL

時価総額

$103.6億

PER

免疫細胞治療の新興企業。IMPT-314が第1/2相のT細胞免疫療法を開発・展開。2024年にImmPACTを約3,130万ドルで買収、2024年2月に最大1.5億ドルの株式販売契約締結。米国（カリフォルニア・ワシントン）中心に展開。

	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-250	-183	-235	-343
Acquired IPR&D expense	-	-	-	87
Impairment of long-lived assets	-	-	-	51
Stock-based compensation expense	62	82	47	33
Depreciation and amortization expense	14	18	20	20
Net amortization and accretion on marketable securities	-2	1	10	15
Impairment of other investments	-	5	13	13
Change in fair value of contingent consideration payable	-	-	-	4
Non-cash lease income	-	-	2	2
Loss on property and equipment disposals, net	-1	-0	-2	-1
Change in fair value of success payment liabilities	4	-5	-3	-1
Gain on marketable equity security	-	-	-	0
Fair Value Adjustment of Warrants	0	1	-	-
Gain on other investments	-	3	-	-
Prepaid expenses, other current assets and other assets	7	2	-3	-2
Accounts payable	0	1	1	-3
Accrued liabilities and other current liabilities	5	-0	-1	-1
Deferred revenue	-11	-85	-	-
Operating lease liabilities, non-current	13	5	-	-
Other non-current liabilities	4	-0	-0	-0
Net cash used in operating activities	-126	-170	-164	-162
Purchases of property and equipment	66	24	3	0
Purchases of marketable securities	673	406	477	395
Maturities of marketable securities	617	419	664	549
Acquisition of assets, net of cash acquired	-	-	-	31
Net cash provided by (used in) investing activities	-122	-12	184	122
Proceeds from Stock Options Exercised	9	10	0	0
Proceeds from Stock Plans	-	2	2	1
Taxes paid related to net share settlement of equity awards	-	0	0	0
Net cash provided by financing activities	401	11	2	1
Net (decrease) increase in cash, cash equivalents and restricted cash	153	-170	22	-39
Cash Paid For Amounts Included In Measurement Of Lease Liabilities	9	11	11	11
Cash received for amounts related to tenant improvement allowances	13	5	-	-
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable	-	-	-	36
Contingent consideration payable	-	-	-	11
Capital Expenditures Incurred but Not yet Paid	5	1	0	0
Acquisition of PACT Series D convertible preferred shares	-	3	-	-
Remeasurement of operating lease right-of-use asset for lease modification	4	0	-	-